MYCN and neoplasm: A MYCN-dependent oncogenic pathway plays a key role in promoting the aggressive, intrinsically resistant disease phenotype [6], in part by modulating the expression of ATP-binding cassette transporters driving active efflux of chemotherapeutics from tumor cells [7].